Dianomi Therapeutics is a development stage biopharmaceutical company focused on creating innovative treatments for autoimmune diseases. Utilizing its proprietary Mineral Coated Microparticle (MCM) technology, the company aims to enhance the stability, safety, and efficacy of proven drugs through sustained release delivery systems. This technology is designed to improve patient outcomes by ensuring that medications are released in a controlled manner over an extended period.

Dianomi Therapeutics primarily serves patients suffering from autoimmune diseases, a market characterized by chronic conditions where the immune system attacks the body's own tissues. The company operates within the biopharmaceutical sector, targeting a niche yet significant segment of the healthcare market.

The business model of Dianomi Therapeutics revolves around the development and eventual commercialization of its drug candidates. Revenue generation is expected to come from licensing agreements, partnerships with larger pharmaceutical companies, and eventually, the sale of its proprietary treatments.

The company is currently in the development stage, meaning it is focused on research and clinical trials to validate its technology and drug candidates. Funding for these activities is secured through investments, such as the recent $7MM Preferred Stock Offering launched by US Capital Global.

Keywords: biopharmaceutical, autoimmune diseases, drug delivery, sustained release, MCM technology, clinical trials, healthcare innovation, patient outcomes, licensing agreements, pharmaceutical partnerships.